The congress, held from 6–9 September 2025, offered a dynamic platform where clinicians, researchers and industry, convened to push the boundaries of lung cancer science. The content from WCLC is currently hosted on our Lung Cancer Channel on VJOncology. If you are interested in supporting Independent Medical Education through our channels, please get in touch here .

As always, the goal behind the scenes was simple: to capture the most compelling conversations, amplify expert opinion, and distil complex data into digestible, engaging media.

Our editors’ top picks from WCLC 2025:

Alessio Cortellini, MD

Updates in EGFRm NSCLC at WCLC 2025: FLAURA2, ACROSS 2 & HARMONi

Alessio Cortellini, MD, Bio-Medico University, Rome, Italy, discusses recent developments in EGFR-mutated non-small cell lung cancer (NSCLC).

Ana Baramidze, MD, PhD

EMPOWER-Lung 3: 5-year results of cemiplimab & chemotherapy in NSCLC

Ana Baramidze, MD, PhD, Todua Clinic, Tbilisi, Georgia, discusses 5-year results from Phase III EMPOWER-Lung 3 (NCT03409614) of cemiplimab plus chemotherapy versus chemotherapy in untreated advanced NSCLC without EGFR, ALK, or ROS1 alterations.

Regan Memmott, MD, PhD 

Safety of osimertinib plus tegavivint in first-line EGFR-mutant NSCLC

Regan Memmott, MD, PhD, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA, outlines results from a Phase Ib trial (NCT04780568) of osimertinib with tegavivint as first-line therapy in patients with metastatic EGFR-mutated NSCLC. 

Hidehito Horinouchi, MD, PhD

Advances in ADCs for lung cancer at WCLC 2025

Hidehito Horinouchi, MD, PhD, National Cancer Center Hospital, Tokyo, Japan, gives an overview of recent updates in antibody-drug conjugates for lung cancer. 

John Varlotto, MD

EA5181: timing of durvalumab with CRT in unresectable stage III NSCLC

John Varlotto, MD, Marshall University, Huntington, WV, USA, discusses results from the Phase III EA5181 trial (NCT04092283) of concurrent plus consolidative durvalumab with chemoradiotherapy versus consolidative durvalumab alone in unresectable stage III NSCLC. 

We hope that through our lens, you get both the clarity of the science and the excitement of being in the room where it’s happening. If you missed WCLC, or want to discover expert insights from the meeting, all our congress coverage will be available on the WCLC 2025 page .

About VJOncology
The Video Journal of Oncology (VJOncology) is a leader in oncology news and education, providing healthcare professionals from around the globe with easy access to the latest updates in solid tumor research and expert opinion. Our Editorial Board and Team work closely to capture the most important and relevant information from major congresses and meetings, presenting this in engaging and easily-digestible digital formats for community oncologists to explore.

The continued success of VJOncology is in no small part down to independent support from industry. If you’re interested in supporting one of our Disease Channels or one of our other medical education programs, please get in contact with us here .

Written by Henry Shippey, Partnerships Manager at Magdalen Medical Publishing